Onapgo (apomorphine) and Vyalev (foscarbidopa/foslevodopa) - Prior Authorization
Customize your policy alerts
Sign up for all harvard pilgrim health care policy alerts
Know when harvard pilgrim health care releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization policy for coverage of Onapgo (apomorphine hydrochloride) and Vyalev (foscarbidopa/foslevodopa) for adults with advanced Parkinson's disease under Harvard Pilgrim and affiliated Tufts commercial and specified public products.
Added coverage criteria for Onapgo (apomorphine).
Template updated to remove CareLink from the Medical Necessity Guideline template and updated plan name references.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.